IL1R2 and neoplasm: Results from this study suggested that patients with CRC may harbor tumor-infiltrating Tregs with a specific protein signature, including the co-stimulatory molecules (OX40, 4-1BB), cytokine receptors (IL1R2, IL21R, CCR8, CD30), and co-inhibitory molecules (PD-L1, TIGIT).